Veracyte reported preliminary Q4 revenue of $138–$140 million, topping consensus, and raised guidance for 2026 with expected double-digit revenue growth. The South San Francisco diagnostics firm said testing revenue drove gains, with testing volume up about 16% in the quarter and full-year 2025 revenue expected near $515–$517 million. Veracyte guided 2026 revenue of $570–$582 million, reflecting continued expansion of its genomic testing footprint and new-test contributions planned for the year.